948880-79-3Relevant academic research and scientific papers
N-[5-(5-fluoropyridin-3-yl)-1H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): A medicinal chemistry effort toward an α7 nicotinic acetylcholine receptor agonist preclinical candidate
Zanaletti, Riccardo,Bettinetti, Laura,Castaldo, Cristiana,Ceccarelli, Ilaria,Cocconcelli, Giuseppe,Comery, Thomas A.,Dunlop, John,Genesio, Eva,Ghiron, Chiara,Haydar, Simon N.,Jow, Flora,Maccari, Laura,Micco, Iolanda,Nencini, Arianna,Pratelli, Carmela,Scali, Carla,Turlizzi, Elisa,Valacchi, Michela
supporting information, p. 10277 - 10281 (2013/01/16)
α7 nicotinic acetylcholine receptors (α7 nAChR) represent promising therapeutic candidates for the treatment of cognitive impairment associated with Alzheimer's disease (AD) and schizophrenia. A medicinal chemistry effort around previously reported compound 1 (SEN15924, WAY-361789) led to the identification of 12 (SEN78702, WYE-308775) a potent and selective full agonist of the α7 nAChR that demonstrated improved plasma stability, brain levels, and efficacy in behavioral cognition models.
